Dept of Medical Oncology - external affiliates

Research output

Research output per year 2003 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

• 157 Article
• 13 Review article
• 10 Doctoral thesis 1 (Research UU / Graduation UU)
• 9 Meeting Abstract
• 19 More
  • 9 Comment/Letter to the editor
  • 6 Doctoral thesis 2 (Research NOT UU / Graduation UU)
  • 4 Letter

Research output per year

Research output per year

Search results

• 2024

  Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy

  Geurts, B. S., Zeverijn, L. J., van Berge Henegouwen, J. M., van der Wijngaart, H., Hoes, L. R., de Wit, G. F., Spiekman, I. A., Battaglia, T. W., van Beek, D. M., Roepman, P., Jansen, A. M., de Leng, W. W., Broeks, A., Labots, M., van Herpen, C. M., Gelderblom, H., Verheul, H. M., Snaebjornsson, P. & Voest, E. E., Jul 2024, In: Journal of Pathology. 263, 3, p. 288-299 12 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  • Turcot syndrome 100%
  • Microsatellite Instability 82%
  • Immunotherapy 59%
  • Whole Genome Sequencing 58%
  • Neoplasms 16%

• Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab

  Zwart, K., van Nassau, S. C. M. W., van der Baan, F. H., Koopman, M., Snaebjornsson, P., van Gestel, A. J., Vink, G. R. & Roodhart, J. M. L., Jul 2024, In: British Journal of Cancer. 131, 1, p. 110-116 7 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  • encorafenib 100%
  • Cetuximab 64%
  • Survival Analysis 49%
  • Colorectal Neoplasms 40%
  • Population 20%
• 2023

  CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients

  Aug 2023, In: Clinical Pharmacokinetics. 62, 8, p. 1129-1139 11 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Cytochrome P-450 CYP3A 100%
  • Phosphotransferases 68%
  • Genotype 63%
  • Single Nucleotide Polymorphism 33%
  • Neoplasms 28%
  6 Downloads (Pure)

• Design and statistics of pharmacokinetic drug-drug, herb-drug, and food-drug interaction studies in oncology patients

  Lanser, D. A. C., Van der Kleij, M. B. A., Veerman, G. D. M., Steeghs, N., Huitema, A. D. R., Mathijssen, R. H. J. & Oomen-de Hoop, E., Jul 2023, In: Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie. 163, 6 p., 114823.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Food-Drug Interactions 100%
  • Polypharmacy 83%
  • Statistics 52%
  • Pharmacokinetics 51%
  • Cross-Over Studies 41%
  14 Downloads (Pure)

• Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities

  Spanjaart, A. M., Pennings, E. R. A., Kos, M., Mutsaers, P. G. N. J., Lugtenburg, P. J., van Meerten, T., van Doesum, J. A., Minnema, M. C., Jak, M., van Dorp, S., Vermaat, J. S. P., van der Poel, M. W. M., van Oijen, M. G. H., Kuipers, M. T., Nijhof, I. S. & Kersten, M. J., 1 Mar 2023, In: JCO oncology practice. 19, 3, p. e407-e416 10 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Chimeric Antigen Receptors 100%
  • Cell- and Tissue-Based Therapy 70%
  • Signs and Symptoms 64%
  • caregiver 63%
  • Caregivers 63%
  16 Downloads (Pure)

• Een vrouw met kanker en een opvallende venetekening

  Translated title of the contribution: An exceptional venous pattern in a patient with cancerFranken, M. D., Röckmann-Helmbach, H. & Bijlsma, R. M., 19 Apr 2023, In: Nederlands Tijdschrift voor Geneeskunde. 167, d7382.

  Research output: Contribution to journal › Article › Academic › peer-review

  • Carboplatin 100%
  • Carcinosarcoma 40%
  • Paclitaxel 30%
  • Neoplasms 28%
  • Hypersensitivity 24%

• Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

  Geurts, B. S., Battaglia, T. W., van Berge Henegouwen, J. M., Zeverijn, L. J., de Wit, G. F., Hoes, L. R., van der Wijngaart, H., van der Noort, V., Roepman, P., de Leng, W. W. J., Jansen, A. M. L., Opdam, F. L., de Jonge, M. J. A., Cirkel, G. A., Labots, M., Hoeben, A., Kerver, E. D., Bins, A. D., Erdkamp, F. G. L., van Rooijen, J. M., & 6 othersHoutsma, D., Hendriks, M. P., de Groot, J-W. B., Verheul, H. M. W., Gelderblom, H. & Voest, E. E., Dec 2023, In: BMC Cancer. 23, 1, 205.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • durvalumab 100%
  • Microsatellite Instability 71%
  • DNA Mismatch Repair 69%
  • Biomarkers 37%
  • Safety 33%
  8 Downloads (Pure)

• Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling

  Angus, L., Smid, M., Wilting, S. M., Bos, M. K., Steeghs, N., Konings, I. R. H. M., Tjan-Heijnen, V. C. G., van Riel, J. M. G. H., van de Wouw, A. J., Cpct Consortium, Cuppen, E., Lolkema, M. P., Jager, A., Sleijfer, S. & Martens, J. W. M., 4 Sept 2023, In: Cancers. 15, 17, 14 p., 4416.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Estrogen Receptors 100%
  • Breast Neoplasms 68%
  • RNA Sequence Analysis 39%
  • Genes 35%
  • Mitogen-Activated Protein Kinases 35%
  6 Downloads (Pure)

• Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors

  van de Geer, W. S., Mathijssen, R. H. J., van Riet, J., Steeghs, N., Labots, M., van Herpen, C., Devriese, L. A., Tjan-Heijnen, V. C. G., Voest, E. E., Sleijfer, S., Martens, J. W. M., Cuppen, E., van de Werken, H. J. G. & Bins, S., Mar 2023, In: Biomedicine and Pharmacotherapy. 159, 114210.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Whole Exome Sequencing 100%
  • Whole Genome Sequencing 97%
  • Protein Kinase Inhibitors 44%
  • Drug Resistance 38%
  • Pharmaceutical Preparations 34%
  6 Downloads (Pure)

• Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer

  Veerman, G. D. M., Boosman, R. J., Jebbink, M., Oomen-de Hoop, E., van der Wekken, A. J., Bahce, I., Hendriks, L. E. L., Croes, S., Steendam, C. M. J., de Jonge, E., Koolen, S. L. W., Steeghs, N., van Schaik, R. H. N., Smit, E. F., Dingemans, A-M. C., Huitema, A. D. R. & Mathijssen, R. H. J., May 2023, In: EClinicalMedicine. 59, 11 p., 101955.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • osimertinib 100%
  • ATP Binding Cassette Transporter, Subfamily G, Member 2 96%
  • Non-Small Cell Lung Carcinoma 56%
  • Central Nervous System 46%
  • Pharmaceutical Preparations 25%
  21 Downloads (Pure)

• Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials

  Zeverijn, L. J., Looze, E. J., Thavaneswaran, S., van Berge Henegouwen, J. M., Simes, R. J., Hoes, L. R., Sjoquist, K. M., van der Wijngaart, H., Sebastian, L., Geurts, B. S., Lee, C. K., de Wit, G. F., Espinoza, D., Roepman, P., Lin, F. P., Jansen, A. M. L., de Leng, W. W. J., van der Noort, V., Leek, L. V. M., de Vos, F. Y. F. L., & 5 othersvan Herpen, C. M. L., Gelderblom, H., Verheul, H. M. W., Thomas, D. M. & Voest, E. E., 1 Oct 2023, In: International Journal of Cancer. 153, 7, p. 1413-1422 10 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  • ribociclib 100%
  • palbociclib 90%
  • Cyclin D 79%
  • Pharmaceutical Preparations 23%
  • Neoplasms 18%

• Multiomics of Colorectal Cancer Organoids Reveals Putative Mediators of Cancer Progression Resulting from SMAD4 Inactivation

  Dijkstra, J. J., Neikes, H. K., Rezaeifard, S., Ma, X., Voest, E. E., Tauriello, D. V. F. & Vermeulen, M., 6 Jan 2023, In: Journal of Proteome Research. 22, 1, p. 138-151 14 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Oncogenic 100%
  • Organoids 93%
  • Antitumor 65%
  • Colorectal Neoplasms 56%
  • Neoplasm Metastasis 33%

• Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity

  Vennin, C., Cattaneo, C. M., Bosch, L., Vegna, S., Ma, X., Damstra, H. G. J., Martinovic, M., Tsouri, E., Ilic, M., Azarang, L., van Weering, J. R. T., Pulver, E., Zeeman, A. L., Schelfhorst, T., Lohuis, J. O., Rios, A. C., Dekkers, J. F., Akkari, L., Menezes, R., Medema, R., & 7 othersBaglio, S. R., Akhmanova, A., Linn, S. C., Lemeer, S., Pegtel, D. M., Voest, E. E. & van Rheenen, J., 12 Jun 2023, In: Cancer Cell. 41, 6, p. 1170-1185.e12 29 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Taxoids 100%
  • T-Lymphocytes 47%
  • Neoplasms 24%
  • Extracellular Vesicles 15%
  • Peripheral Nervous System Diseases 13%
  24 Downloads (Pure)

• The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies

  de Joode, K., van de Geer, W. S., van Leenders, G. J. L. H., Hamberg, P., Westgeest, H. M., Beeker, A., Oosting, S. F., van Rooijen, J. M., Beerepoot, L. V., Labots, M., Mathijssen, R. H. J., Lolkema, M. P., Cuppen, E., Sleijfer, S., van de Werken, H. J. G. & van der Veldt, A. A. M., 3 Jul 2023, In: Scientific Reports. 13, 1, p. 1-15 10720.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Renal Cell Carcinoma 100%
  • RNA Sequence Analysis 63%
  • Whole Genome Sequencing 54%
  • Therapeutics 17%
  • Survival 10%
  3 Downloads (Pure)

• Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)

  Meertens, M., Muntinghe-Wagenaar, M. B., Sikkema, B. J., Lopez-Yurda, M., Retèl, V. P., Paats, M. S., Ter Heine, R., Schuuring, E., Timens, W., Touw, D. J., van Boven, J. F. M., de Langen, A. J., Hashemi, S. M. S., Hendriks, L. E. L., Croes, S., van den Heuvel, M. M., Dingemans, A. M. C., Mathijssen, R. H. J., Smit, E. F., Huitema, A. D. R., & 2 othersSteeghs, N. & van der Wekken, A. J., 2023, In: Frontiers in oncology. 13, 9 p., 1136221.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • artificial lung expanding compound 100%
  • CH5424802 80%
  • Anaplastic Lymphoma Kinase 63%
  • Drug Monitoring 54%
  • Non-Small Cell Lung Carcinoma 42%
  10 Downloads (Pure)

• Trends in Distal Esophageal and Gastroesophageal Junction Cancer Care: The Dutch Nationwide Ivory Study

  Kalff, M. C., Henegouwen, M. I. V. B., Baas, P. C., Bahadoer, R. R., Belt, E. J. T., Brattinga, B., Claassen, L., Ćosović, A., Crull, D., Daams, F., van Dalsen, A. D., Dekker, J. W. T., van Det, M. J., Drost, M., van Duijvendijk, P., Eshuis, W. J., van Esser, S., Gaspersz, M. P., Görgec, B., Groenendijk, R. P. R., & 37 othersHartgrink, H. H., van der Harst, E., Haveman, J. W., Heisterkamp, J., van Hillegersberg, R., Kelder, W., Kingma, B. F., Koemans, W. J., Kouwenhoven, E. A., Lagarde, S. M., Lecot, F., van der Linden, P. P., Luyer, M. D. P., Nieuwenhuijzen, G. A. P., Olthof, P. B., van der Peet, D. L., Pierie, J-P. E. N., Pierik, E. G. J. M. R., Plat, V. D., Polat, F., Rosman, C., Ruurda, J. P., van Sandick, J. W., Scheer, R., Slootmans, C. A. M., Sosef, M. N., Sosef, O. V., de Steur, W. O., Stockmann, H. B. A. C., Stoop, F. J., Voeten, D. M., Vugts, G., Vijgen, G. H. E. J., Weeda, V. B., Wiezer, M. J., van Oijen, M. G. H. & Gisbertz, S. S., Apr 2023, In: Annals of surgery. 277, 4, p. 619-628 10 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  • Esophagogastric Junction 100%
  • Esophagectomy 90%
  • Postoperative Care 30%
  • Minimally Invasive Surgical Procedures 29%
  • Esophageal Neoplasms 26%
• 2022

  A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach

  Mulder, J., van Stuijvenberg, O. C., van Hennik, P. B., Voest, E. E., Pasmooij, A. M. G., Stoyanova-Beninska, V. & de Boer, A., 14 Jun 2022, In: Frontiers in medicine. 9, p. 1-12 893400.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Marketing 100%
  • ARRY-470 54%
  • entrectinib 54%
  • United States Food and Drug Administration 36%
  • pembrolizumab 25%
  9 Downloads (Pure)

• Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?

  Embaby, A., van Merendonk, L., Steeghs, N., Beijnen, J. & Huitema, A., 2022, In: Frontiers in oncology. 12, 940582.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Carvedilol 100%
  • Hemangiosarcoma 92%
  • Receptors, Adrenergic, beta 85%
  • Labetalol 70%
  • Pindolol 68%
  14 Downloads (Pure)

• Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients

  Schipper, L. J., Monkhorst, K., Samsom, K. G., Bosch, L. J. W., Snaebjornsson, P., Boven, H. V., Roepman, P., van der Kolk, L. E., van Houdt, W. J., van der Graaf, W. T. A., Meijer, G. A. & Voest, E. E., 16 Jan 2022, In: Cancers. 14, 2, p. 1-15 436.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Whole Genome Sequencing 100%
  • Sarcoma 81%
  • Pathologists 21%
  • Biomarkers 13%
  • Workflow 11%
  1 Citation (Scopus)

  3 Downloads (Pure)

• Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics

  Schipper, L. J., Samsom, K. G., Snaebjornsson, P., Battaglia, T., Bosch, L. J. W., Lalezari, F., Priestley, P., Shale, C., van den Broek, A. J., Jacobs, N., Roepman, P., van der Hoeven, J. J. M., Steeghs, N., Vollebergh, M. A., Marchetti, S., Cuppen, E., Meijer, G. A., Voest, E. E. & Monkhorst, K., Dec 2022, In: ESMO open. 7, 6, 100611.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Neoplasms 100%
  • Whole Genome Sequencing 90%
  • Unknown Primary Neoplasms 24%
  • Genome 21%
  • Colorectal Neoplasms 12%
  8 Downloads (Pure)

• Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma

  Nakauma-González, J. A., Rijnders, M., van Riet, J., van der Heijden, M. S., Voortman, J., Cuppen, E., Mehra, N., van Wilpe, S., Oosting, S. F., Rijstenberg, L. L., Westgeest, H. M., Zwarthoff, E. C., de Wit, R., van der Veldt, A. A. M., van de Werken, H. J. G., Lolkema, M. P. J. & Boormans, J. L., Apr 2022, In: European Urology. 81, 4, p. 331-336 6 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Carcinoma 100%
  • Whole Genome Sequencing 43%
  • RNA Sequence Analysis 42%
  • Clinical Decision-Making 39%
  • DNA Sequence Analysis 37%

• Delivering precision oncology to patients with cancer

  Mateo, J., Steuten, L., Aftimos, P., André, F., Davies, M., Garralda, E., Geissler, J., Husereau, D., Martinez-Lopez, I., Normanno, N., Reis-Filho, J. S., Stefani, S., Thomas, D. M., Westphalen, C. B. & Voest, E., Apr 2022, In: Nature Medicine. 28, 4, p. 658-665 8 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  • Drug 100%
  • Genomics 95%
  • Neoplasms 61%
  • Shared Decision Making 58%
  • Drug Development 44%
  27 Citations (Scopus)

• Detection and localization of early- and late-stage cancers using platelet RNA

  In 't Veld, S. G. J. G., Arkani, M., Post, E., Antunes-Ferreira, M., D'Ambrosi, S., Vessies, D. C. L., Vermunt, L., Vancura, A., Muller, M., Niemeijer, A-L. N., Tannous, J., Meijer, L. L., Le Large, T. Y. S., Mantini, G., Wondergem, N. E., Heinhuis, K. M., van Wilpe, S., Smits, A. J., Drees, E. E. E., Roos, E., & 96 othersLeurs, C. E., Tjon Kon Fat, L-A., van der Lelij, E. J., Dwarshuis, G., Kamphuis, M. J., Visser, L. E., Harting, R., Gregory, A., Schweiger, M. W., Wedekind, L. E., Ramaker, J., Zwaan, K., Verschueren, H., Bahce, I., de Langen, A. J., Smit, E. F., van den Heuvel, M. M., Hartemink, K. J., Kuijpers, M. J. E., Oude Egbrink, M. G. A., Griffioen, A. W., Rossel, R., Hiltermann, T. J. N., Lee-Lewandrowski, E., Lewandrowski, K. B., De Witt Hamer, P. C., Kouwenhoven, M., Reijneveld, J. C., Leenders, W. P. J., Hoeben, A., Verdonck-de Leeuw, I. M., Leemans, C. R., Baatenburg de Jong, R. J., Terhaard, C. H. J., Takes, R. P., Langendijk, J. A., de Jager, S. C., Kraaijeveld, A. O., Pasterkamp, G., Smits, M., Schalken, J. A., Łapińska-Szumczyk, S., Łojkowska, A., Żaczek, A. J., Lokhorst, H., van de Donk, N. W. C. J., Nijhof, I., Prins, H-J., Zijlstra, J. M., Idema, S., Baayen, J. C., Teunissen, C. E., Killestein, J., Besselink, M. G., Brammen, L., Bachleitner-Hofmann, T., Mateen, F., Plukker, J. T. M., Heger, M., De Mast, Q., Lisman, T., Pegtel, D. M., Bogaard, H-J., Jassem, J., Supernat, A., Mehra, N., Gerritsen, W. R., de Kroon, C. D., Lok, C. A. R., Piek, J. M. J., Steeghs, N., van Houdt, W. J., Brakenhoff, R. H., Sonke, G. S., Verheul, H. M. W., Giovannetti, E., Kazemier, G., Sabrkhany, S., Schuuring, E., Sistermans, E. A., Wolthuis, R., Meijers-Heijboer, H., Dorsman, J., Oudejans, C., Ylstra, B., Westerman, B. A., van den Broek, D., Koppers-Lalic, D., Wesseling, P., Nilsson, R. J. A., Vandertop, W. P., Noske, D. P., Tannous, B. A., Sol, N., Best, M. G. & Wurdinger, T., 12 Sept 2022, In: Cancer Cell. 40, 9, p. 999-1009.e6

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Blood Platelets 100%
  • RNA 88%
  • Neoplasms 41%
  • Hematologic Tests 8%
  • Early Detection of Cancer 8%
  17 Citations (Scopus)

  6 Downloads (Pure)

• Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments

  Kester, L., Seinstra, D., van Rossum, A. G. J., Vennin, C., Hoogstraat, M., van der Velden, D., Opdam, M., van Werkhoven, E., Hahn, K., Nederlof, I., Lips, E. H., Mandjes, I. A. M., van Leeuwen-Stok, A. E., Canisius, S., van Tinteren, H., Imholz, A. L. T., Portielje, J. E. A., Bos, M. E. M. M., Bakker, S. D., Rutgers, E. J., & 9 othersHorlings, H. M., Wesseling, J., Voest, E. E., Wessels, L. F. A., Kok, M., Oosterkamp, H. M., van Oudenaarden, A., Linn, S. C. & van Rheenen, J., 1 Mar 2022, In: Clinical Cancer Research. 28, 5, p. 960-971 12 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Cellular Microenvironment 100%
  • Epithelial Cells 57%
  • Breast Neoplasms 50%
  • Survival 44%
  • Therapeutics 13%
  6 Downloads (Pure)

• Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting

  Boosman, R. J., Jebbink, M., Veldhuis, W. B., Groenland, S. L., van Veggel, B. A. M. H., Moeskops, P., de Langen, A. J., Beijnen, J. H., Smit, E. F., Huitema, A. D. R. & Steeghs, N., Oct 2022, In: Pharmaceutical Research. 39, 10, p. 2507-2514 8 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  • Osimertinib 100%
  • osimertinib 82%
  • ErbB Receptors 49%
  • Non-Small Cell Lung Carcinoma 46%
  • Mutation 43%

• Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer

  Sept 2022, In: Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie. 153, 113393.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Sorafenib 100%
  • Drug Monitoring 93%
  • Thyroid Neoplasms 82%
  • Liver Neoplasms 80%
  • Aggressive Fibromatosis 13%
  7 Downloads (Pure)

• Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice

  Samsom, K. G., Schipper, L. J., Roepman, P., Bosch, L. J., Lalezari, F., Klompenhouwer, E. G., de Langen, A. J., Buffart, T. E., Riethorst, I., Schoenmaker, L., Schout, D., van der Noort, V., van den Berg, J. G., de Bruijn, E., van der Hoeven, J. J., van Snellenberg, H., van der Kolk, L. E., Cuppen, E., Voest, E. E., Meijer, G. A., & 1 othersMonkhorst, K., Oct 2022, In: Journal of Pathology. 258, 2, p. 179-188 10 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Whole Genome Sequencing 100%
  • Pathology 54%
  • Standard of Care 27%
  • Neoplasms 27%
  • Biomarkers 18%
  7 Downloads (Pure)

• Is age just a number? A population pharmacokinetic study of gemcitabine

  Boosman, R. J., Crombag, M-R. B. S., van Erp, N. P., Beijnen, J. H., Steeghs, N. & Huitema, A. D. R., May 2022, In: Cancer Chemotherapy and Pharmacology. 89, 5, p. 697-705 9 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  • Gemcitabine 100%
  • gemcitabine 74%
  • Pharmacokinetics 50%
  • Population 26%
  • Dose 11%

• Patients With Rare Cancers in the Drug Rediscovery Protocol (DRUP) benefit from Genomics - Guided Treatment

  Hoes, L. R., van Berge Henegouwen, J. M., van der Wijngaart, H., Zeverijn, L. J., van der Velden, D. L., van de Haar, J., Roepman, P., de Leng, W. J., Jansen, A. M. L., van Werkhoven, E., van der Noort, V., Huitema, A. D. R., Gort, E. H., de Groot, J. W. B., Kerver, E. D., de Groot, D. J., Erdkamp, F., Beerepoot, L. V., Hendriks, M. P., Smit, E. F., & 10 othersvan der Graaf, W. T. A., van Herpen, C. M. L., Labots, M., Hoeben, A., Morreau, H., Lolkema, M. P., Cuppen, E., Gelderblom, H. J., Verheul, H. M. W. & Voest, E. E., 1 Apr 2022, In: Clinical cancer research : an official journal of the American Association for Cancer Research. 28, 7, p. 1402-1411 10 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Genomics 100%
  • Pharmaceutical Preparations 40%
  • Neoplasms 31%
  • Therapeutics 16%
  • Molecular Pathology 7%
  3 Downloads (Pure)

• Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors: A Cross-Sectional Study

  Naaktgeboren, W. R., Groen, W. G., Jacobse, J. N., Steggink, L. C., Walenkamp, A. M. E., van Harten, W. H., Stuiver, M. M., Aaronson, N. K., Aleman, B. M. P., van der Meer, P., Schaapveld, M., Sonke, G. S., Gietema, J. A., van Leeuwen, F. E. & May, A. M., Jun 2022, In: J AM Coll Cardiol CardioOnc. 4, 2, p. 183-191 9 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Cancer Survivors 100%
  • Survivors 80%
  • Cross-Sectional Studies 59%
  • Exercise 59%
  • Breast Neoplasms 58%
  6 Downloads (Pure)

• Prognosis of interval distant metastases after neoadjuvant chemoradiotherapy for esophageal cancer

  Kroese, T. E., Dijksterhuis, W. P. M., van Rossum, P. S. N., Verhoeven, R. H. A., Mook, S., Mohammad, N. H., Hulshof, M. C. C. M., van Berge Henegouwen, M. I., van Oijen, M. G. H., Ruurda, J. P., van Laarhoven, H. W. M. & van Hillegersberg, R., Feb 2022, In: The Annals of Thoracic Surgery. 113, 2, p. 482-490 9 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Chemoradiotherapy 100%
  • Esophageal Neoplasms 95%
  • Neoplasm Metastasis 57%
  • Survival 43%
  • Confidence Intervals 23%

• Recurrent Disease after Esophageal Cancer Surgery: A Substudy of The Dutch Nationwide Ivory Study

  Kalff, M. C., Henckens, S. P. G., Voeten, D. M., Heineman, D. J., Hulshof, M. C. C. M., van Laarhoven, H. W. M., Eshuis, W. J., Baas, P. C., Bahadoer, R. R., Belt, E. J. T., Brattinga, B., Claassen, L., Ćosović, A., Crull, D., Daams, F., van Dalsen, A. D., Dekker, J. W. T., van Det, M. J., Drost, M., Duijvendijk, P. V., & 41 othersEsser, S. V., Gaspersz, M. P., Görgec, B., Groenendijk, R. P. R., Hartgrink, H. H., Harst, E. V. D., Haveman, J. W., Heisterkamp, J., Hillegersberg, R. V., Kelder, W., Kingma, B. F., Koemans, W. J., Kouwenhoven, E. A., Lagarde, S. M., Lecot, F., van der Linden, P. P., Luyer, M. D. P., Nieuwenhuijzen, G. A. P., Olthof, P. B., van der Peet, D. L., Pierie, J-P. E., Pierik, E. G. J. M. R., Plat, V. D., Polat, F., Rosman, C., Ruurda, J. P., van Sandick, J. W., Scheer, R., Slootmans, C. AM., Sosef, M. N., Sosef, O. V., de Steur, W. O., Stockmann, H. B. A. C., Stoop, F. J., Vugts, G., Vijgen, G. H. E. J., Weeda, V. B., Wiezer, M. J., van Oijen, M. G. H., van Berge Henegouwen, M. I. & Gisbertz, S. S., Nov 2022, In: Annals of surgery. 276, 5, p. 806-813 8 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  • Esophageal Neoplasms 100%
  • Survival 54%
  • Recurrence 47%
  • Esophagectomy 32%
  • Confidence Intervals 24%

• Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia

  Stein, E. M., DeAngelo, D. J., Chromik, J., Chatterjee, M., Bauer, S., Lin, C-C., Suarez, C., De Vos, F., Steeghs, N., Cassier, P. A., Tai, D., Kiladjian, J-J., Yamamoto, N., Mous, R., Esteve, J., Minami, H., Ferretti, S., Guerreiro, N., Meille, C., Radhakrishnan, R., & 5 othersPereira, B., Mariconti, L., Halilovic, E., Fabre, C. & Carpio, C., 1 Mar 2022, In: Clinical cancer research : an official journal of the American Association for Cancer Research. 28, 5, p. 870-881 12 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • siremadlin 100%
  • Leukemia 35%
  • Hematologic Neoplasms 22%
  • Neoplasms 14%
  • Confidence Intervals 13%
  4 Downloads (Pure)

• Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib

  Boosman, R. J., de Gooijer, C. J., Groenland, S. L., Burgers, J. A., Baas, P., van der Noort, V., Beijnen, J. H., Huitema, A. D. R. & Steeghs, N., Apr 2022, In: Pharmaceutical Research. 39, 4, p. 669-676 8 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  • Erlotinib 100%
  • Ritonavir 80%
  • Erlotinib Hydrochloride 80%
  • Phosphotransferase Inhibitor 79%
  • Label 55%

• RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells

  Zhang, Z., Kong, X., Ligtenberg, M. A., van Hal-van Veen, S. E., Visser, N. L., de Bruijn, B., Stecker, K., van der Helm, P. W., Kuilman, T., Hoefsmit, E. P., Vredevoogd, D. W., Apriamashvili, G., Baars, B., Voest, E. E., Klarenbeek, S., Altelaar, M. & Peeper, D. S., 21 Jun 2022, In: Cell Reports Medicine. 3, 6, p. 1-25 100655.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Ablation 100%
  • Antitumor 79%
  • Antigen 72%
  • Natural Killer T-Cells 68%
  • Immunotherapy 50%
  1 Citation (Scopus)

• The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

  Feb 2022, In: Nature Cancer. 3, 2, p. 251-261 11 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Clinical Decision Support Systems 100%
  • Neoplasms 24%
  • Point-of-Care Systems 17%
  • High-Throughput Nucleotide Sequencing 14%
  • Decision Making 12%
  6 Citations (Scopus)

  21 Downloads (Pure)

• Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer

  van Berge Henegouwen, J. M., Jebbink, M., Hoes, L. R., van der Wijngaart, H., Zeverijn, L. J., van der Velden, D. L., Roepman, P., de Leng, W. W. J., Jansen, A. M. L., van Werkhoven, E., van der Noort, V., van der Wekken, A. J., de Langen, A. J., Voest, E. E., Verheul, H. M. W., Smit, E. F. & Gelderblom, H., Aug 2022, In: European Journal of Cancer. 171, p. 114-123 10 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • pertuzumab 100%
  • Trastuzumab 75%
  • Epidermal Growth Factor 62%
  • Non-Small Cell Lung Carcinoma 57%
  • Exons 53%
  11 Downloads (Pure)
• 2021

  Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol

  Mc Laughlin, A. M., Schmulenson, E., Teplytska, O., Zimmermann, S., Opitz, P., Groenland, S. L., Huitema, A. D. R., Steeghs, N., Müller, L., Fuxius, S., Illerhaus, G., Joerger, M., Mayer, F., Fuhr, U., Holdenrieder, S., Hempel, G., Scherf-Clavel, O., Jaehde, U., Kloft, C. & For The On-Target Study Consortium, 1 Dec 2021, In: Cancers. 13, 24, 6281.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Drug Monitoring 100%
  • Pharmaceutical Preparations 35%
  • Drug-Related Side Effects and Adverse Reactions 26%
  • cabozantinib 23%
  • Axitinib 22%
  9 Downloads (Pure)

• Driver mutations occur frequently in metastases of well-differentiated small intestine neuroendocrine tumours

  Samsom, K. G., Levy, S., van Veenendaal, L. M., Roepman, P., Kodach, L. L., Steeghs, N., Valk, G. D., Wouter Dercksen, M., Kuhlmann, K. F. D., Verbeek, W. H. M., Meijer, G. A., Tesselaar, M. E. T. & van den Berg, J. G., Mar 2021, In: Histopathology. 78, 4, p. 556-566 11 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  • Neuroendocrine Tumors 100%
  • Small Intestine 80%
  • Neoplasm Metastasis 54%
  • Mutation 49%
  • Whole Genome Sequencing 25%

• Exposure-response analyses of anaplastic lymphoma kinase inhibitors crizotinib and alectinib in non-small-cell lung cancer patients

  Groenland, S. L., Geel, D. R., Janssen, J. M., de Vries, N., Rosing, H., Beijnen, J. H., Burgers, J. A., Smit, E. F., Huitema, A. D. R. & Steeghs, N., Feb 2021, In: Clinical Pharmacology and Therapeutics. 109, 2, p. 394-402 9 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • CH5424802 100%
  • Crizotinib 85%
  • Anaplastic Lymphoma Kinase 79%
  • Non-Small Cell Lung Carcinoma 53%
  • Confidence Intervals 17%
  3 Downloads (Pure)

• Intra-tumoral pharmacokinetics of pazopanib in combination with radiotherapy in patients with non-metastatic soft-tissue sarcoma

  Molenaar-Kuijsten, L., van Meekeren, M., Verheijen, R. B., Bovée, J. V. M. G., Fiocco, M., Thijssen, B., Rosing, H., Huitema, A. D. R., Miah, A. B., Gelderblom, H., Haas, R. L. M. & Steeghs, N., 18 Nov 2021, In: Cancers. 13, 22, p. 1-12 5780.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • pazopanib 100%
  • Sarcoma 63%
  • Pharmacokinetics 50%
  • Radiotherapy 46%
  • Neoplasms 21%
  9 Downloads (Pure)

• Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors

  Verheijen, R. B., van Duijl, T. T., van den Heuvel, M. M., Vessies, D., Muller, M., Beijnen, J. H., Janssen, J. M., Schellens, J. H. M., Steeghs, N., van den Broek, D. & Huitema, A. D. R., Feb 2021, In: Cancer Chemotherapy and Pharmacology. 87, 2, p. 269-276 8 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  • Circulating Tumor DNA 100%
  • Non-Small Cell Lung Carcinoma 62%
  • Mutation 58%
  • Plasma 16%
  • Progression-Free Survival 15%
  1 Citation (Scopus)

• Precision Dosing of Targeted Therapies Is Ready for Prime Time

  Groenland, S. L., Verheijen, R. B., Joerger, M., Mathijssen, R. H. J., Sparreboom, A., Beijnen, J. H., Beumer, J. H., Steeghs, N. & Huitema, A. D. R., 15 Dec 2021, In: Clinical cancer research : an official journal of the American Association for Cancer Research. 27, 24, p. 6644-6652 9 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  • Pharmacokinetics 100%
  • Pharmaceutical Preparations 41%
  • Drug Monitoring 38%
  • Precision Medicine 35%
  • Drug Interactions 32%

• The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets

  van Riet, J., van de Werken, H. J. G., Cuppen, E., Eskens, F. A. L. M., Tesselaar, M., van Veenendaal, L. M., Klümpen, H-J., Dercksen, M. W., Valk, G. D., Lolkema, M. P., Sleijfer, S. & Mostert, B., 29 Jul 2021, In: Nature Communications. 12, 1, p. 1-14 4612.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • neoplasms 100%
  • tumors 59%
  • Mutation 52%
  • genome 32%
  • grade 23%
  12 Downloads (Pure)

• Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features

  Mendelaar, P. A. J., Smid, M., van Riet, J., Angus, L., Labots, M., Steeghs, N., Hendriks, M. P., Cirkel, G. A., van Rooijen, J. M., Ten Tije, A. J., Lolkema, M. P., Cuppen, E., Sleijfer, S., Martens, J. W. M. & Wilting, S. M., 25 Jan 2021, In: Nature Communications. 12, 1, 11 p., 574.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • metastasis 100%
  • sequencing 93%
  • genome 89%
  • Whole Genome Sequencing 80%
  • cancer 64%
  8 Downloads (Pure)

• Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics

  Molenaar-Kuijsten, L., Jacobs, B. A. W., Kurk, S. A., May, A. M., Dorlo, T. P. C., Beijnen, J. H., Steeghs, N. & Huitema, A. D. R., Jul 2021, In: Cancer Medicine. 10, 14, p. 4781-4789 9 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Capecitabine 100%
  • Skeletal Muscle 62%
  • Pharmacokinetics 59%
  • alpha-fluoro-beta-alanine 22%
  • Fluorouracil 17%
  4 Downloads (Pure)
• 2020

  Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme

  May 2020, In: European Journal of Cancer. 130, p. 32-38 7 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Abiraterone Acetate 100%
  • Drug Monitoring 73%
  • Pharmacokinetics 47%
  • Food 44%
  • Fasting 12%
  6 Downloads (Pure)

• Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients

  Jul 2020, In: Clinical Pharmacokinetics. 59, 7, p. 941-948 8 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  • pazopanib 100%
  • Pharmacokinetics 50%
  • Prospective Studies 42%
  • Costs and Cost Analysis 41%
  • Appointments and Schedules 40%

• Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose

  Roosendaal, J., Groenland, S. L., Rosing, H., Lucas, L., Venekamp, N., Nuijen, B., Huitema, A. D. R., Beijnen, J. H. & Steeghs, N., Aug 2020, In: European Journal of Clinical Pharmacology. 76, 8, p. 1075-1082 8 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Imatinib Mesylate 100%
  • Biological Availability 79%
  • Pharmacokinetics 8%
  • Deuterium 8%
  • Gastrointestinal Stromal Tumors 7%
  9 Downloads (Pure)

• Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples

  Mar 2020, In: British Journal of Cancer. 122, 7, p. 953-956 4 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  • Tumor Burden 100%
  • Neoplasms 33%
  • Genes 24%
  • Exome 17%
  • Intelligence 15%